2-Methylen-3-ethoxy-propionsaeure-amid | 63144-92-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-Methylen-3-ethoxy-propionsaeure-amid
• 英文别名: 2-(Ethoxymethyl)acrylamide；2-(ethoxymethyl)prop-2-enamide
• CAS: 63144-92-3
• 化学式: C₆H₁₁NO₂
• mdl: MFCD19209615
• 分子量: 129.159
• InChiKey: XCESYZPOWKEXHF-UHFFFAOYSA-N

物化性质

• 沸点：
  276.9±32.0 °C(Predicted)
• 密度：
  0.996±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] UNIVERSAL METHYLATION PROFILING METHODS<br/>[FR] PROCÉDÉS UNIVERSELS D'ÉTABLISSEMENT DE PROFILS DE MÉTHYLATION
  申请人：UNIV COLUMBIA

  公开号：WO2016100864A1

  公开（公告）日：2016-06-23

  The present invention provides a method of determining whether cytosine residues present at a predetermined positions within a singl strand of a double stranded DNA of known sequence are methylated as well as compounds for carrying out this method. The present invention also provides a process of producing a derivative of a double-stranded DNA comprising contacting the double-stranded DNA with a CpG methyltransferase and an S-adenosylmethionine analog.

  本发明提供了一种确定已知序列的双链DNA中单链的特定位置是否存在甲基化的方法，以及用于执行该方法的化合物。本发明还提供了一种生产双链DNA衍生物的过程，包括将双链DNA与CpG甲基转移酶和S-腺苷甲硫氨酸类似物接触。
• [EN] UNIVERSAL METHYLATION PROFILING METHODS<br/>[FR] PROCÉDÉS UNIVERSELS DE PROFILAGE DE LA MÉTHYLATION
  申请人：UNIV COLUMBIA

  公开号：WO2014204861A1

  公开（公告）日：2014-12-24

  The present invention provides a compound having the adenosylmethionine structure, wherein the sulfur atom of the methionine moiety is modified with alkene or succinimide groups, wherein R1, R2 and R3 are independently H, alkyl, aryl, C(0)NH2, C(0)R', CN, N02, C (O)R', S(0),NHR'; wherein X is 0 or NR'; wherein R' is H, alkyl or aryl; and wherein n is an integer from 1 to 8, with the proviso that, when substituent is a propene derivative, and n is 1, at least one of R1, R2, or R3 is other than H.

  本发明提供了一种具有腺苷甲硫氨酸结构的化合物，其中蛋氨酸部分的硫原子经过烯烃或琥珀酰亚胺基团修饰，其中R1、R2和R3独立地为H、烷基、芳基、C(0)NH2、C(0)R'、CN、NO2、C(O)R'、S(0)、NHR'；其中X为0或NR'；其中R'为H、烷基或芳基；n为1至8之间的整数，但当取代基为丙烯衍生物且n为1时，至少有一个R1、R2或R3不为H。
• Proline ester and preparation containing the same for percutaneous administration
  申请人：Furuishi Takayuki

  公开号：US20050288232A1

  公开（公告）日：2005-12-29

  A proline ester represented by the following formula (I): wherein R 1 represents a hydroxy-lower alkyl group, a lower alkoxy-lower alkyl group, or a lower alkoxy-lower alkoxy-lower alkyl group or a pharmaceutically acceptable salt thereof. The proline ester (I) of the present invention and a pharmaceutically acceptable salt thereof are useful as a prodrug of enalaprilat, which is a medicine useful for preventing or treating circulatory diseases such as hypertension, cardiac diseases (e.g., cardiac hypertrophy, cardiac failure, and myocardial infarct), nephritis, and apoplexy. Thus, a drug containing the ester or a salt thereof is preferably formulated to a percutaneous preparation, particularly a patch, from the viewpoint of medicinal activity and use.

  以下是翻译结果： 一种由以下式子(I)所表示的脯氨酸酯： 其中R1代表羟基-低烷基基团、低烷氧基-低烷基基团或低烷氧基-低烷氧基-低烷基基团，或其药学上可接受的盐。本发明的脯氨酸酯(I)及其药学上可接受的盐可作为依那普利酸的前药，该药物可用于预防或治疗循环系统疾病，如高血压、心脏疾病（如心肌肥大、心力衰竭和心肌梗死）、肾炎和中风。因此，含有该酯或其盐的药物最好从药效和用途的角度来看，制成经皮制剂，特别是贴片。
• Percutaneous absorption preparation
  申请人：Suzuki Yasuyuki

  公开号：US20090264521A1

  公开（公告）日：2009-10-22

  Percutaneous absorption preparations which make it possible to absorb compounds having a melatonin receptor agonist activity via a convenient administration system, have favorable blood-drug-concentration-time profile and can exert a therapeutic effect on a disease caused by a decrease in secretion of melatonin at night.

  经皮吸收制剂可以通过方便的给药系统吸收具有褪黑素受体激动剂活性的化合物，具有良好的血药浓度时间曲线，并可以对由于夜间褪黑素分泌减少而引起的疾病产生治疗效果。
• PERCUTANEOUS ABSORPTION PREPARATIONS
  申请人：SUZUKI Yasuyuki

  公开号：US20120309823A1

  公开（公告）日：2012-12-06

  Percutaneous absorption preparations which make it possible to absorb compounds having a melatonin receptor agonist activity via a convenient administration system, have favorable blood-drug-concentration-time profile and can exert a therapeutic effect on a disease caused by a decrease in secretion of melatonin at night.

  经皮吸收制剂使得通过便捷的给药系统吸收具有褪黑素受体激动剂活性的化合物成为可能，具有良好的血药浓度-时间曲线，并且可以对由夜间褪黑素分泌减少引起的疾病产生治疗效果。